AJG Maintained by Argus Research -- Price Target Raised to $300
Argus Research maintained Arthur J. Gallagher (AJG) at a “Buy” rating on Sept. 29, 2023. Analyst Kevin Heal raised the price target to $300 from $267. The article cites a GF Value™ of $338.08 versus a $251.21 current price, and a GF Score™ of 92/100, plus net insider selling of $0.6M over three months.
How this was made
The 30-second read
Why it matters
Traders can treat this as incremental bullish sentiment for AJG, but the article lacks fresh operational or financial disclosures (no earnings, guidance, or transaction).
Market read
A PT increase from $267 to $300 with a maintained Buy rating can influence short-term positioning, but it is not a fundamental catalyst.
What to watch
The article notes net insider selling of $0.6M over three months, which could temper enthusiasm despite the PT increase.
Background
The piece is a GuruFocus summary of an Argus Research analyst action on AJG, including a maintained Buy rating and a raised price target.
Ticker impact
Argus maintained a Buy rating on Arthur J. Gallagher and raised its price target from $267 to $300, citing improved outlook.
Near-term bias upward, with limited follow-through unless additional fundamental catalysts emerge.
This is a sell-side target update rather than an earnings, guidance, or deal disclosure; impact is likely sentiment-driven and incremental.
Market effects
Supports positive sentiment for insurance brokerage/financial services, but does not introduce sector-wide new data.
No specific regional catalyst beyond general international revenue mix.
No global macro or cross-border transaction details provided.
Counterpoint
A higher price target may reflect valuation assumptions rather than new AJG fundamentals, so price may already discount the change.
Key entities
- companyArthur J. Gallagher
Insurance brokerage firm discussed as the subject of the analyst rating and price target update.
- analyst_firmArgus Research
Maintained AJG at Buy and raised the price target from $267 to $300.
- analystKevin Heal
Argus analyst credited with the price target increase.



